Senti Biosciences Holdings, Inc. filed an 8-K on October 26, 2026, reporting the October 21, 2026 completion of its merger with ST NewCo Limited and the simultaneous entry into a Contingent Value Rights Agreement governing up to $60.0 million in potential future cash payments to equityholders.

Key Highlights

  • Merger closed October 21, 2026: Senti Merger Sub, Inc. merged with and into Senti Holdings, Inc. (Midco), with Midco surviving as a wholly owned subsidiary of ST NewCo Limited (f/k/a Celadon Partners SPV 35 Limited).
  • CVR Agreement established: Midco and Continental Stock Transfer and Trust Company entered into a Contingent Value Rights Agreement on October 21, 2026, governing contingent cash payments tied to SENTI-202 milestones.
  • Up to $60.0 million in milestone payments: The aggregate amount payable under the CVR Agreement shall not exceed $60.0 million, tied to three separate milestones, all subject to a seventh-anniversary deadline from closing.
  • Three milestone triggers: A pro rata share of $10.0 million upon FDA BLA filing and acceptance for SENTI-202; $20.0 million upon FDA BLA approval; and $30.0 million upon cumulative worldwide net sales exceeding $200.0 million.
  • One CVR per share of common stock: Each holder of Company Common Stock as of the CVR Record Date will receive one CVR per share held; holders of Company Stock Options, Company RSUs, and Company Warrants are also entitled to receive CVRs.
  • CVRs are non-transferable and non-certificated: According to the filing, CVRs will not have voting or dividend rights, will not represent equity or ownership interests in Parent or Midco, and will not be transferable except in limited circumstances.
  • Highly speculative: The filing states that "the CVRs and the possibility of receiving any payment pursuant to the CVRs are highly speculative and subject to numerous factors outside the control of Parent or its affiliates."

Senti Biosciences Merger Terms and SENTI-202 Contingent Value Rights Explained

According to the 8-K filed by Senti Biosciences Holdings, Inc. (NASDAQ:SNTI) on October 26, 2026, the company completed its previously announced merger on October 21, 2026. The transaction was governed by the Agreement and Plan of Merger dated July 14, 2026, among the company, Midco, Opco (Senti Biosciences, Inc.), Parent (ST NewCo Limited), and Merger Sub. Upon closing, Merger Sub merged into Midco, and each outstanding share of Midco common stock - other than shares owned by Midco or a subsidiary of Midco, which were canceled - was automatically canceled and converted into the right to receive Milestone Payment Amounts in the form of CVRs distributed to the company's equityholders.

The CVR Agreement, entered into on the Closing Date between Midco and Continental Stock Transfer and Trust Company as Rights Agent, sets out three contingent cash milestones, each tied to the company's Logic Gated off-the-shelf CAR-NK cell therapy known as SENTI-202. The first milestone of $10.0 million is triggered by the FDA's acceptance of a biologics license application for SENTI-202, or the passing of the 60-day review period without rejection. The second milestone of $20.0 million is triggered upon FDA approval of that BLA. The third milestone of $30.0 million is contingent on cumulative worldwide net sales of SENTI-202 exceeding $200.0 million from first commercial sale through the seventh anniversary of the Closing Date. The filing states there can be no assurance that any payment pursuant to the CVRs will ever be paid.

The filing further discloses that, immediately prior to the closing effective time, all outstanding Company Stock Options became fully vested and exercisable, and all outstanding Company RSUs became fully vested. Holders of Company Stock Options, Company RSUs, and Company Warrants that remain outstanding as of immediately prior to the CVR Record Date will each be entitled to receive CVRs upon exercise or settlement, reduced by applicable withholding taxes, in accordance with the terms of the CVR Agreement. The CVR Record Date had not yet been fixed as of the filing date, with the Board stating it intends to fix that date after the closing.

What Was Disclosed

Senti Biosciences Holdings, Inc. reported the October 21, 2026 closing of its merger with ST NewCo Limited and the entry into a CVR Agreement providing up to $60.0 million in contingent payments linked to three SENTI-202 regulatory and commercial milestones, all expiring on the seventh anniversary of closing.